Please assess the completion status of the following clinical trial:

Trial Title: Does IV Ondansetron Prevent Pruritus After Intrathecal Morphine in Pediatric Patients?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 3-17 years~* weight \</= 100kg~* scheduled for urologic or orthopedic procedure necessitating intrathecal morphine~* ability to use verbal or pictorial pain assessment tools and techniques~* informed consent and (if applicable) assent~Exclusion Criteria:~* Inability to use verbal or pictorial pain scoring scales~* hypersensitivity to selective 5-HT receptor antagonists~* diagnosed congenital long QT syndrome~* severe hepatic impairment~* pregnancy or nursing mothers

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Ondansetron IV (Type: EXPERIMENTAL): Ondansetron IV X1 intraoperatively (0.1 mg/kg in 5 mLs) Ondansetron IV X 4 (Q 6 hrs for 24 hrs) (0.1 mg/kg in 5 mLs)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Comparator: This arm will receive (in a blinded fashion) a volume-matched placebo intraoperatively X1 as well as IV every 6 hrs for 24 hours postoperatively. (X4)

Based on this trial design, predict the completion outcome and termination type (if applicable).